Abstract
The DFT-B3LYP method, with the basis set 6-31G (d, p), was employed to calculate some quantum chemical descriptors of 33 biphenyl imidazole derivatives as bombesin receptor subtype-3 agonists. The descriptors were then employed to establish a quantitative structure activity relationship (QSAR) using combination of principal component analysis (PCA) and radial basis function neural network (RBF). The statistical results indicate that the correlation coefficient (R2) and cross validation using leave-one-out were 0.968 and 0.963, respectively. To validate the predictive power of the resulting model, external validation was carried out on the test set. The results show that the PCA-RBF model has not only favorable estimation stability but also good prediction power. Furthermore, it can be concluded that the agonist activity of studied compounds toward the bombesin receptor subtype-3 depends on the electronic distribution.
Keywords: Bombesin receptor subtype-3 agonists, Density functional theory, Radial basis function neural network, QSAR, Biphenyl imidazole derivatives, Nonlinear relationship.
Letters in Drug Design & Discovery
Title:A Combined DFT and QSAR Calculations to Study Substituted Biphenyl imidazoles as Bombesin Receptor Subtype-3 Agonists
Volume: 11 Issue: 5
Author(s): Mohsen Shahlaei, Amin Nowroozi and Reza Khodarahmi
Affiliation:
Keywords: Bombesin receptor subtype-3 agonists, Density functional theory, Radial basis function neural network, QSAR, Biphenyl imidazole derivatives, Nonlinear relationship.
Abstract: The DFT-B3LYP method, with the basis set 6-31G (d, p), was employed to calculate some quantum chemical descriptors of 33 biphenyl imidazole derivatives as bombesin receptor subtype-3 agonists. The descriptors were then employed to establish a quantitative structure activity relationship (QSAR) using combination of principal component analysis (PCA) and radial basis function neural network (RBF). The statistical results indicate that the correlation coefficient (R2) and cross validation using leave-one-out were 0.968 and 0.963, respectively. To validate the predictive power of the resulting model, external validation was carried out on the test set. The results show that the PCA-RBF model has not only favorable estimation stability but also good prediction power. Furthermore, it can be concluded that the agonist activity of studied compounds toward the bombesin receptor subtype-3 depends on the electronic distribution.
Export Options
About this article
Cite this article as:
Shahlaei Mohsen, Nowroozi Amin and Khodarahmi Reza, A Combined DFT and QSAR Calculations to Study Substituted Biphenyl imidazoles as Bombesin Receptor Subtype-3 Agonists, Letters in Drug Design & Discovery 2014; 11 (5) . https://dx.doi.org/10.2174/1570180811666131203002858
DOI https://dx.doi.org/10.2174/1570180811666131203002858 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Possible Targets of Herbals for Type 3 Diabetes: A Review
Current Traditional Medicine FTY720: A Most Promising Immunosuppressant Modulating Immune Cell Functions
Mini-Reviews in Medicinal Chemistry Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design ImmunoPET in Neoplasms of Gastrointestinal Tract, Liver and Pancreas in the XXIst Century: Bridging the Gap Between Diagnosis and Therapy
Reviews on Recent Clinical Trials Chemoprevention Gene Therapy (CGT): Novel Combinatorial Approach for Preventing and Treating Pancreatic Cancer
Current Molecular Medicine The Therapeutic Potential of ADAM15
Current Pharmaceutical Design Biology and Impact of Signal Transducers and Activators of Transcription and Their Regulators as Targets in Cancer Therapy
Current Signal Transduction Therapy A Simple Identification of Novel Carbonyl Reducing Enzymes in the Metabolism of the Tobacco Specific Carcinogen NNK
Drug Metabolism Letters How to Make a Non-Antigenic Protein (Auto) Antigenic: Molecular Complementarity Alters Antigen Processing and Activates Adaptive-Innate Immunity Synergy
Anti-Cancer Agents in Medicinal Chemistry Intracellular Proton Pumps as Targets in Chemotherapy: V-ATPases and Cancer
Current Pharmaceutical Design Metastasis Suppressors: Basic and Translational Advances
Current Pharmaceutical Biotechnology Left-Right Asymmetry in Embryonic Development and Breast Cancer: Common Molecular Determinants?
Current Medicinal Chemistry Suppression of Cancer Invasiveness by Dietary Compounds
Mini-Reviews in Medicinal Chemistry Cyclic Peptides that Govern Signal Transduction Pathways: From Prokaryotes to Multi-Cellular Organisms
Current Topics in Medicinal Chemistry The Synthesis and Anticancer Potentials of Quinoline Analogues: A Review of Literature
Mini-Reviews in Organic Chemistry Role of Lipoxins and Resolvins as Anti-Inflammatory and Proresolving Mediators in Colon Cancer
Current Molecular Medicine Oleamide Derivatives are Prototypical Anti-Metastasis Drugs that Act by Inhibiting Connexin 26
Current Drug Safety Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Metabolic Effects of Bile Acids in the Gut in Health and Disease
Current Medicinal Chemistry Calcium Channels and Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery